Palvella Therapeutics (PVLA) Cash & Current Investments (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Cash & Current Investments for 14 consecutive years, with $261.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 246.25% year-over-year to $261.9 million; the TTM figure through Mar 2026 stood at $261.9 million (up 246.25% YoY), while the FY2025 annual figure was $58.0 million, down 30.65% from the prior year.
• Cash & Current Investments improved to $261.9 million in Q1 2026 per PVLA's latest filing, from $58.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $261.9 million in Q1 2026 and bottomed at $6.2 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $69.1 million across 5 years, with a median of $63.6 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Current Investments sank 89.05% — and 2025, when it jumped 1110.4%.
• Palvella Therapeutics' Cash & Current Investments stood at $59.2 million in 2022, then sank by 72.42% to $16.3 million in 2023, then surged by 412.27% to $83.6 million in 2024, then slumped by 30.65% to $58.0 million in 2025, then surged by 351.61% to $261.9 million in 2026.
• Business Quant data shows PVLA's Cash & Current Investments at $261.9 million in Q1 2026, $58.0 million in Q4 2025, and $63.6 million in Q3 2025.